Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

BACKGROUND: Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. The URAT1 inhibitors probenecid and benzbromarone a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arthritis Res Ther
Auteurs principaux: Miner, Jeffrey, Tan, Philip K., Hyndman, David, Liu, Sha, Iverson, Cory, Nanavati, Payal, Hagerty, David T., Manhard, Kimberly, Shen, Zancong, Girardet, Jean-Luc, Yeh, Li-Tain, Terkeltaub, Robert, Quart, Barry
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5048659/
https://ncbi.nlm.nih.gov/pubmed/27716403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1107-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires